The aim of this study was to examine the association between metabolic associated fatty liver disease (MAFLD) in participants who had undergone cholecystectomy and those who had not undergone cholecystectomy. MAFLD is defined as hepatic steatosis(with ultrasonography) entity in addition to the presence of overweight or obesity, diabetes mellitus, or evidence of metabolic dysfunction. In this way, the long-term effects of cholecystectomy surgeries, which are commonly performed in the society and thought to be harmless, will be evaluated.
Cholecystectomy is known to be a harmless operation with low perioperative mortality and morbidity. However, the unexplained increase in metabolic disorders in cholecystectomy patients has led to the need for further investigation of cholecystectomy patients. Non-alcoholic fatty liver disease is an important health problem with an average prevalence of 25% worldwide and serious hepatic and systemic complications. The aim of this study was to examine the association of cholecystectomy with metabolic dysfunction associated fatty liver disease (MAFLD), which is an important public health problem in the long-term. This case-controlled cross-sectional study was planned to evaluate the relationship between patients who had undergone cholecystectomy with MAFLD. MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, diabetes mellitus, or evidence of metabolic dysfunction. The study included 86 participants with cholecystectomy and 63 participants without cholecystectomy. It was planned to compare the participants according to the diagnostic criteria for MAFLD (with or without MAFLD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
149
MAFLD is defined as hepatic steatosis entity in addition to the presence of overweight or obesity, DM, or evidence of metabolic dysfunction. Metabolic dysfunction (two or more of the following) 1. waist circumference ≥ 90 cm in men and 88 cm in women, 2. blood pressure ≥ 130/85 mmHg or on specific drug treatment, 3. plasma triglycerides (TG) ≥ 150 mg/dl or on specific drug treatment, 4. plasma high-density lipoprotein cholesterol (HDL-C) \< 40 mg/dl for men and 50 mg/dl for women or on specific drug treatment, 5. prediabetes (FBS 100 to 125 mg/dl or HbA1c 5.7 to 6.4%), 6. homeostasis model assessment of insulin resistance (HOMA-IR) score ≥ 2.5.
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital
Ankara, Turkey (Türkiye)
diabetes mellitus
fasting plasma glucose \>126mg/dL
Time frame: through study completion, an average of 4 months
definition of overweight
BMI \>25 kg/m2
Time frame: through study completion, an average of 4 months
Upper limits of waist circumference
≥102 cm in men and 88 cm in women
Time frame: through study completion, an average of 4 months
Definition of pre-diabetes
fasting plasma glucose of 100-125 mg/dL
Time frame: through study completion, an average of 4 months
Blood pressure upper limit
≥130/85 mmHg
Time frame: through study completion, an average of 4 months
HDL-cholesterol levels
\<40 mg/dL for males and \<50 mg/dL for females.
Time frame: through study completion, an average of 4 months
Triglyceride levels
≥1.70 mmol/L
Time frame: through study completion, an average of 4 months
Diagnosis of MAFLD
hepatic steatosis + (diabetes mellitus and/or overweight and/or metabolic dysfunction) metabolic dysfunction is defined as the presence of at least two criteria(Pre-diabetes, TG, HDL, blood pressure, waist circumference)
Time frame: through study completion, an average of 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.